Review



anti human lap tgfβ1 neutralizing antibodies  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    R&D Systems anti human lap tgfβ1 neutralizing antibodies
    Anti Human Lap Tgfβ1 Neutralizing Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 20 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti human lap tgfβ1 neutralizing antibodies/product/R&D Systems
    Average 92 stars, based on 20 article reviews
    anti human lap tgfβ1 neutralizing antibodies - by Bioz Stars, 2026-03
    92/100 stars

    Images



    Similar Products

    92
    R&D Systems anti human lap tgfβ1 neutralizing antibodies
    Anti Human Lap Tgfβ1 Neutralizing Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti human lap tgfβ1 neutralizing antibodies/product/R&D Systems
    Average 92 stars, based on 1 article reviews
    anti human lap tgfβ1 neutralizing antibodies - by Bioz Stars, 2026-03
    92/100 stars
      Buy from Supplier

    90
    Thermo Fisher anti-tgfβ1 neutralizing antibody
    <t>TGF</t> and FGF up-regulate PD-L1 and skew macrophage polarization . (a, b) Expression of PD-L1 on the surface of fibroblast-like cells detected by FCM. (c, d, f, g) Expression of CD86 and CD206 in WT-MEF or PD-L1 KO MEF detected by FCM. Macrophages were co-cultured with untreated, or FGF-2 and TGF-β1 pretreated fibroblasts were washed with PBS, blocked in 5% FBS and two color-stained to identify M1 (CD86) and M2 (CD206) macrophage subpopulations.(e, h) Expression of CD16, CD86 and CD206 in macrophages co-cultured with pretreated fibroblast-like cells detected by immunofluorescence staining.(i) Pretreating WT or PD-L1-/- fibroblasts (fixed with Paraformaldehyde or not) affect activated macrophages TNF-α, IL-6 and IL-10 production in a contact-dependent manner. *p < 0.05, **p < 0.01.
    Anti Tgfβ1 Neutralizing Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-tgfβ1 neutralizing antibody/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    anti-tgfβ1 neutralizing antibody - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    R&D Systems anti-tgfβ1 neutralizing antibody
    Expression of <t>TGFβ</t> on the surface of exosomes and its effect on regulatory T cells expansion. The expression of <t>TGFβ1</t> ( A ) and TGFβ2 ( B ) on the surface of exosomes were evaluated using the TGF-β Magnetic Luminex Performance Assay on exosomes released by unstimulated (CTRL, white column) o LPS-activated tumor cells (LPS, black column). Data are shown as mean (n = 8) ± SD. *Difference with exosomes released by unstimulated tumor cells, P < 0.05. ( B ) Exosomes were coupled to ExoFlow beads, stained with monoclonal antibodies against TGFβ1 and analyzed by FACS. Representative plots of the FACS analyses for staining of control (black line) and of LPS-derived exosomes (red line) are shown. ( D–F ) CD4+ T cells, isolated from PBMCs by negative selection, were stimulated with anti-CD3, anti-CD28 and IL-2 in the presence of exosomes released by unstimulated (CTRL, white column) o LPS-activated tumor cells (LPS, black column). The percentage of effector (CD4+/CD25−/FoxP3−) or regulatory T cells (CD4+/CD25+/FoxP3+) was determined by fluorescence activated flow cytometry (FACS) on day 4. Representative plots for CD25 and Foxp3 staining are shown and histograms represent the ratio between the percentage of effector and regulatory T cells (T eff /T reg ). In a separate set of experiments, exosomes were pre-treated with neutralizing anti-TGFβ1 antibody. Data are shown as mean (n = 6) ± SD. *difference with the untreated cells, P < 0.05 ; **difference with untreated cells, P < 0.005 , $ difference with exosomes treated cells released by LPS-activated cells.
    Anti Tgfβ1 Neutralizing Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-tgfβ1 neutralizing antibody/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    anti-tgfβ1 neutralizing antibody - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    R&D Systems neutralizing anti-(α)tgfβ1 antibody
    Expression of <t>TGFβ</t> on the surface of exosomes and its effect on regulatory T cells expansion. The expression of <t>TGFβ1</t> ( A ) and TGFβ2 ( B ) on the surface of exosomes were evaluated using the TGF-β Magnetic Luminex Performance Assay on exosomes released by unstimulated (CTRL, white column) o LPS-activated tumor cells (LPS, black column). Data are shown as mean (n = 8) ± SD. *Difference with exosomes released by unstimulated tumor cells, P < 0.05. ( B ) Exosomes were coupled to ExoFlow beads, stained with monoclonal antibodies against TGFβ1 and analyzed by FACS. Representative plots of the FACS analyses for staining of control (black line) and of LPS-derived exosomes (red line) are shown. ( D–F ) CD4+ T cells, isolated from PBMCs by negative selection, were stimulated with anti-CD3, anti-CD28 and IL-2 in the presence of exosomes released by unstimulated (CTRL, white column) o LPS-activated tumor cells (LPS, black column). The percentage of effector (CD4+/CD25−/FoxP3−) or regulatory T cells (CD4+/CD25+/FoxP3+) was determined by fluorescence activated flow cytometry (FACS) on day 4. Representative plots for CD25 and Foxp3 staining are shown and histograms represent the ratio between the percentage of effector and regulatory T cells (T eff /T reg ). In a separate set of experiments, exosomes were pre-treated with neutralizing anti-TGFβ1 antibody. Data are shown as mean (n = 6) ± SD. *difference with the untreated cells, P < 0.05 ; **difference with untreated cells, P < 0.005 , $ difference with exosomes treated cells released by LPS-activated cells.
    Neutralizing Anti (α)Tgfβ1 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/neutralizing anti-(α)tgfβ1 antibody/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    neutralizing anti-(α)tgfβ1 antibody - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology anti tgf β1 neutralizing antibody
    Expression of <t>TGFβ</t> on the surface of exosomes and its effect on regulatory T cells expansion. The expression of <t>TGFβ1</t> ( A ) and TGFβ2 ( B ) on the surface of exosomes were evaluated using the TGF-β Magnetic Luminex Performance Assay on exosomes released by unstimulated (CTRL, white column) o LPS-activated tumor cells (LPS, black column). Data are shown as mean (n = 8) ± SD. *Difference with exosomes released by unstimulated tumor cells, P < 0.05. ( B ) Exosomes were coupled to ExoFlow beads, stained with monoclonal antibodies against TGFβ1 and analyzed by FACS. Representative plots of the FACS analyses for staining of control (black line) and of LPS-derived exosomes (red line) are shown. ( D–F ) CD4+ T cells, isolated from PBMCs by negative selection, were stimulated with anti-CD3, anti-CD28 and IL-2 in the presence of exosomes released by unstimulated (CTRL, white column) o LPS-activated tumor cells (LPS, black column). The percentage of effector (CD4+/CD25−/FoxP3−) or regulatory T cells (CD4+/CD25+/FoxP3+) was determined by fluorescence activated flow cytometry (FACS) on day 4. Representative plots for CD25 and Foxp3 staining are shown and histograms represent the ratio between the percentage of effector and regulatory T cells (T eff /T reg ). In a separate set of experiments, exosomes were pre-treated with neutralizing anti-TGFβ1 antibody. Data are shown as mean (n = 6) ± SD. *difference with the untreated cells, P < 0.05 ; **difference with untreated cells, P < 0.005 , $ difference with exosomes treated cells released by LPS-activated cells.
    Anti Tgf β1 Neutralizing Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti tgf β1 neutralizing antibody/product/Santa Cruz Biotechnology
    Average 96 stars, based on 1 article reviews
    anti tgf β1 neutralizing antibody - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    90
    R&D Systems polyclonal anti-tgfβ1 neutralizing antibody (ab10-na)
    Expression of <t>TGFβ</t> on the surface of exosomes and its effect on regulatory T cells expansion. The expression of <t>TGFβ1</t> ( A ) and TGFβ2 ( B ) on the surface of exosomes were evaluated using the TGF-β Magnetic Luminex Performance Assay on exosomes released by unstimulated (CTRL, white column) o LPS-activated tumor cells (LPS, black column). Data are shown as mean (n = 8) ± SD. *Difference with exosomes released by unstimulated tumor cells, P < 0.05. ( B ) Exosomes were coupled to ExoFlow beads, stained with monoclonal antibodies against TGFβ1 and analyzed by FACS. Representative plots of the FACS analyses for staining of control (black line) and of LPS-derived exosomes (red line) are shown. ( D–F ) CD4+ T cells, isolated from PBMCs by negative selection, were stimulated with anti-CD3, anti-CD28 and IL-2 in the presence of exosomes released by unstimulated (CTRL, white column) o LPS-activated tumor cells (LPS, black column). The percentage of effector (CD4+/CD25−/FoxP3−) or regulatory T cells (CD4+/CD25+/FoxP3+) was determined by fluorescence activated flow cytometry (FACS) on day 4. Representative plots for CD25 and Foxp3 staining are shown and histograms represent the ratio between the percentage of effector and regulatory T cells (T eff /T reg ). In a separate set of experiments, exosomes were pre-treated with neutralizing anti-TGFβ1 antibody. Data are shown as mean (n = 6) ± SD. *difference with the untreated cells, P < 0.05 ; **difference with untreated cells, P < 0.005 , $ difference with exosomes treated cells released by LPS-activated cells.
    Polyclonal Anti Tgfβ1 Neutralizing Antibody (Ab10 Na), supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal anti-tgfβ1 neutralizing antibody (ab10-na)/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    polyclonal anti-tgfβ1 neutralizing antibody (ab10-na) - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    92
    R&D Systems anti tgfβ1 neutralizing antibody
    Expression of <t>TGFβ</t> on the surface of exosomes and its effect on regulatory T cells expansion. The expression of <t>TGFβ1</t> ( A ) and TGFβ2 ( B ) on the surface of exosomes were evaluated using the TGF-β Magnetic Luminex Performance Assay on exosomes released by unstimulated (CTRL, white column) o LPS-activated tumor cells (LPS, black column). Data are shown as mean (n = 8) ± SD. *Difference with exosomes released by unstimulated tumor cells, P < 0.05. ( B ) Exosomes were coupled to ExoFlow beads, stained with monoclonal antibodies against TGFβ1 and analyzed by FACS. Representative plots of the FACS analyses for staining of control (black line) and of LPS-derived exosomes (red line) are shown. ( D–F ) CD4+ T cells, isolated from PBMCs by negative selection, were stimulated with anti-CD3, anti-CD28 and IL-2 in the presence of exosomes released by unstimulated (CTRL, white column) o LPS-activated tumor cells (LPS, black column). The percentage of effector (CD4+/CD25−/FoxP3−) or regulatory T cells (CD4+/CD25+/FoxP3+) was determined by fluorescence activated flow cytometry (FACS) on day 4. Representative plots for CD25 and Foxp3 staining are shown and histograms represent the ratio between the percentage of effector and regulatory T cells (T eff /T reg ). In a separate set of experiments, exosomes were pre-treated with neutralizing anti-TGFβ1 antibody. Data are shown as mean (n = 6) ± SD. *difference with the untreated cells, P < 0.05 ; **difference with untreated cells, P < 0.005 , $ difference with exosomes treated cells released by LPS-activated cells.
    Anti Tgfβ1 Neutralizing Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti tgfβ1 neutralizing antibody/product/R&D Systems
    Average 92 stars, based on 1 article reviews
    anti tgfβ1 neutralizing antibody - by Bioz Stars, 2026-03
    92/100 stars
      Buy from Supplier

    90
    Promega 4 and 5 or 10 µg/ml of a neutralizing polyclonal rabbit anti-tgfβ1 antibody
    Expression of <t>TGFβ</t> on the surface of exosomes and its effect on regulatory T cells expansion. The expression of <t>TGFβ1</t> ( A ) and TGFβ2 ( B ) on the surface of exosomes were evaluated using the TGF-β Magnetic Luminex Performance Assay on exosomes released by unstimulated (CTRL, white column) o LPS-activated tumor cells (LPS, black column). Data are shown as mean (n = 8) ± SD. *Difference with exosomes released by unstimulated tumor cells, P < 0.05. ( B ) Exosomes were coupled to ExoFlow beads, stained with monoclonal antibodies against TGFβ1 and analyzed by FACS. Representative plots of the FACS analyses for staining of control (black line) and of LPS-derived exosomes (red line) are shown. ( D–F ) CD4+ T cells, isolated from PBMCs by negative selection, were stimulated with anti-CD3, anti-CD28 and IL-2 in the presence of exosomes released by unstimulated (CTRL, white column) o LPS-activated tumor cells (LPS, black column). The percentage of effector (CD4+/CD25−/FoxP3−) or regulatory T cells (CD4+/CD25+/FoxP3+) was determined by fluorescence activated flow cytometry (FACS) on day 4. Representative plots for CD25 and Foxp3 staining are shown and histograms represent the ratio between the percentage of effector and regulatory T cells (T eff /T reg ). In a separate set of experiments, exosomes were pre-treated with neutralizing anti-TGFβ1 antibody. Data are shown as mean (n = 6) ± SD. *difference with the untreated cells, P < 0.05 ; **difference with untreated cells, P < 0.005 , $ difference with exosomes treated cells released by LPS-activated cells.
    4 And 5 Or 10 µg/Ml Of A Neutralizing Polyclonal Rabbit Anti Tgfβ1 Antibody, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/4 and 5 or 10 µg/ml of a neutralizing polyclonal rabbit anti-tgfβ1 antibody/product/Promega
    Average 90 stars, based on 1 article reviews
    4 and 5 or 10 µg/ml of a neutralizing polyclonal rabbit anti-tgfβ1 antibody - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    Image Search Results


    TGF and FGF up-regulate PD-L1 and skew macrophage polarization . (a, b) Expression of PD-L1 on the surface of fibroblast-like cells detected by FCM. (c, d, f, g) Expression of CD86 and CD206 in WT-MEF or PD-L1 KO MEF detected by FCM. Macrophages were co-cultured with untreated, or FGF-2 and TGF-β1 pretreated fibroblasts were washed with PBS, blocked in 5% FBS and two color-stained to identify M1 (CD86) and M2 (CD206) macrophage subpopulations.(e, h) Expression of CD16, CD86 and CD206 in macrophages co-cultured with pretreated fibroblast-like cells detected by immunofluorescence staining.(i) Pretreating WT or PD-L1-/- fibroblasts (fixed with Paraformaldehyde or not) affect activated macrophages TNF-α, IL-6 and IL-10 production in a contact-dependent manner. *p < 0.05, **p < 0.01.

    Journal: International Journal of Biological Sciences

    Article Title: Fibroblast-like cells Promote Wound Healing via PD-L1-mediated Inflammation Resolution

    doi: 10.7150/ijbs.69890

    Figure Lengend Snippet: TGF and FGF up-regulate PD-L1 and skew macrophage polarization . (a, b) Expression of PD-L1 on the surface of fibroblast-like cells detected by FCM. (c, d, f, g) Expression of CD86 and CD206 in WT-MEF or PD-L1 KO MEF detected by FCM. Macrophages were co-cultured with untreated, or FGF-2 and TGF-β1 pretreated fibroblasts were washed with PBS, blocked in 5% FBS and two color-stained to identify M1 (CD86) and M2 (CD206) macrophage subpopulations.(e, h) Expression of CD16, CD86 and CD206 in macrophages co-cultured with pretreated fibroblast-like cells detected by immunofluorescence staining.(i) Pretreating WT or PD-L1-/- fibroblasts (fixed with Paraformaldehyde or not) affect activated macrophages TNF-α, IL-6 and IL-10 production in a contact-dependent manner. *p < 0.05, **p < 0.01.

    Article Snippet: 20 mg/mL anti-FGF-2 neutralizing antibody (Sigma Aldrich, St. Louis, MO, USA) and 50 mg/mL anti-TGFβ1 neutralizing antibody (Thermo Fischer Scientific; former Savant, MA, USA) were incubated along with Wound exudate in FACS, where indicated.

    Techniques: Expressing, Cell Culture, Staining, Immunofluorescence

    TGF-β1 together with FGF-2 significantly upregulated fibroblast-like cells PD-L1 at translational levels. (a, b) Polysome profiles of MEF cells treated 24 h with FGF-2 and TGF-β1. One representative profile from three independent experiments is shown. Percentage of transcripts in each polysomal fraction obtained by sucrose-gradient ultracentrifugation was quantified by qRT-PCR (n = 3). (c) Western blot analysis of the indicated proteins in MEF when stimulated by FGF-2 and TGF-β1. Representative blots from two independent experiments are shown. (d, e) PD-L1 is visualized by flow cytometry in MEF cells stimulated by FGF-2 and TGF-β1 and eIF4E inhibitor. One representative experiment of two is shown. *p < 0.05,**p < 0.01.

    Journal: International Journal of Biological Sciences

    Article Title: Fibroblast-like cells Promote Wound Healing via PD-L1-mediated Inflammation Resolution

    doi: 10.7150/ijbs.69890

    Figure Lengend Snippet: TGF-β1 together with FGF-2 significantly upregulated fibroblast-like cells PD-L1 at translational levels. (a, b) Polysome profiles of MEF cells treated 24 h with FGF-2 and TGF-β1. One representative profile from three independent experiments is shown. Percentage of transcripts in each polysomal fraction obtained by sucrose-gradient ultracentrifugation was quantified by qRT-PCR (n = 3). (c) Western blot analysis of the indicated proteins in MEF when stimulated by FGF-2 and TGF-β1. Representative blots from two independent experiments are shown. (d, e) PD-L1 is visualized by flow cytometry in MEF cells stimulated by FGF-2 and TGF-β1 and eIF4E inhibitor. One representative experiment of two is shown. *p < 0.05,**p < 0.01.

    Article Snippet: 20 mg/mL anti-FGF-2 neutralizing antibody (Sigma Aldrich, St. Louis, MO, USA) and 50 mg/mL anti-TGFβ1 neutralizing antibody (Thermo Fischer Scientific; former Savant, MA, USA) were incubated along with Wound exudate in FACS, where indicated.

    Techniques: Quantitative RT-PCR, Western Blot, Flow Cytometry

    PD-L1 positive fibroblast-like cells pretreated by TGF-β1 and FGF-2 promote chronic refractory wound healing in vivo. (a) Representative photographs showing macroscopic excisional wound closure treated with PD-L1 positive and negative MEF in PD-L1-/- C57 BL6 mice. The wild-type and PD-L1-/- mice fibroblast-like cells were isolated and cultured in Dulbecco's modified Eagle's medium (Gibco) supplemented with 10% fetal bovine serum (FBS), 50 units/mL penicillin and 50 units/mL streptomycin (Sigma). Followed by pretreated with TGF-β1 and FGF-2, approximately 1x 10 5 fibroblast-like cells were further suspended in saline and sprayed over the wound area of the mice. (b) Planimetric analysis of wound photographs reveals significantly delayed at 3-5 days after wounding when PD-L1-/- MEF were used. (c) The schematic diagram of the mechanism of PD-L1 regulating wound healing.

    Journal: International Journal of Biological Sciences

    Article Title: Fibroblast-like cells Promote Wound Healing via PD-L1-mediated Inflammation Resolution

    doi: 10.7150/ijbs.69890

    Figure Lengend Snippet: PD-L1 positive fibroblast-like cells pretreated by TGF-β1 and FGF-2 promote chronic refractory wound healing in vivo. (a) Representative photographs showing macroscopic excisional wound closure treated with PD-L1 positive and negative MEF in PD-L1-/- C57 BL6 mice. The wild-type and PD-L1-/- mice fibroblast-like cells were isolated and cultured in Dulbecco's modified Eagle's medium (Gibco) supplemented with 10% fetal bovine serum (FBS), 50 units/mL penicillin and 50 units/mL streptomycin (Sigma). Followed by pretreated with TGF-β1 and FGF-2, approximately 1x 10 5 fibroblast-like cells were further suspended in saline and sprayed over the wound area of the mice. (b) Planimetric analysis of wound photographs reveals significantly delayed at 3-5 days after wounding when PD-L1-/- MEF were used. (c) The schematic diagram of the mechanism of PD-L1 regulating wound healing.

    Article Snippet: 20 mg/mL anti-FGF-2 neutralizing antibody (Sigma Aldrich, St. Louis, MO, USA) and 50 mg/mL anti-TGFβ1 neutralizing antibody (Thermo Fischer Scientific; former Savant, MA, USA) were incubated along with Wound exudate in FACS, where indicated.

    Techniques: In Vivo, Isolation, Cell Culture, Modification, Saline

    Expression of TGFβ on the surface of exosomes and its effect on regulatory T cells expansion. The expression of TGFβ1 ( A ) and TGFβ2 ( B ) on the surface of exosomes were evaluated using the TGF-β Magnetic Luminex Performance Assay on exosomes released by unstimulated (CTRL, white column) o LPS-activated tumor cells (LPS, black column). Data are shown as mean (n = 8) ± SD. *Difference with exosomes released by unstimulated tumor cells, P < 0.05. ( B ) Exosomes were coupled to ExoFlow beads, stained with monoclonal antibodies against TGFβ1 and analyzed by FACS. Representative plots of the FACS analyses for staining of control (black line) and of LPS-derived exosomes (red line) are shown. ( D–F ) CD4+ T cells, isolated from PBMCs by negative selection, were stimulated with anti-CD3, anti-CD28 and IL-2 in the presence of exosomes released by unstimulated (CTRL, white column) o LPS-activated tumor cells (LPS, black column). The percentage of effector (CD4+/CD25−/FoxP3−) or regulatory T cells (CD4+/CD25+/FoxP3+) was determined by fluorescence activated flow cytometry (FACS) on day 4. Representative plots for CD25 and Foxp3 staining are shown and histograms represent the ratio between the percentage of effector and regulatory T cells (T eff /T reg ). In a separate set of experiments, exosomes were pre-treated with neutralizing anti-TGFβ1 antibody. Data are shown as mean (n = 6) ± SD. *difference with the untreated cells, P < 0.05 ; **difference with untreated cells, P < 0.005 , $ difference with exosomes treated cells released by LPS-activated cells.

    Journal: Scientific Reports

    Article Title: Toll-like Receptor-4 Activation Boosts the Immunosuppressive Properties of Tumor Cells-derived Exosomes

    doi: 10.1038/s41598-019-44949-y

    Figure Lengend Snippet: Expression of TGFβ on the surface of exosomes and its effect on regulatory T cells expansion. The expression of TGFβ1 ( A ) and TGFβ2 ( B ) on the surface of exosomes were evaluated using the TGF-β Magnetic Luminex Performance Assay on exosomes released by unstimulated (CTRL, white column) o LPS-activated tumor cells (LPS, black column). Data are shown as mean (n = 8) ± SD. *Difference with exosomes released by unstimulated tumor cells, P < 0.05. ( B ) Exosomes were coupled to ExoFlow beads, stained with monoclonal antibodies against TGFβ1 and analyzed by FACS. Representative plots of the FACS analyses for staining of control (black line) and of LPS-derived exosomes (red line) are shown. ( D–F ) CD4+ T cells, isolated from PBMCs by negative selection, were stimulated with anti-CD3, anti-CD28 and IL-2 in the presence of exosomes released by unstimulated (CTRL, white column) o LPS-activated tumor cells (LPS, black column). The percentage of effector (CD4+/CD25−/FoxP3−) or regulatory T cells (CD4+/CD25+/FoxP3+) was determined by fluorescence activated flow cytometry (FACS) on day 4. Representative plots for CD25 and Foxp3 staining are shown and histograms represent the ratio between the percentage of effector and regulatory T cells (T eff /T reg ). In a separate set of experiments, exosomes were pre-treated with neutralizing anti-TGFβ1 antibody. Data are shown as mean (n = 6) ± SD. *difference with the untreated cells, P < 0.05 ; **difference with untreated cells, P < 0.005 , $ difference with exosomes treated cells released by LPS-activated cells.

    Article Snippet: In a separate set of experiments, SW480-, SW620- and U87-MG-derived exosomes were pre-incubated for 15 min at 37 °C with 0.5 µg/ml of anti-TGFβ1 neutralizing antibody (R&D system) before adding to cells.

    Techniques: Expressing, Luminex, Staining, Derivative Assay, Isolation, Selection, Fluorescence, Flow Cytometry